The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

Nathan P. Wiederhold; Laura K. Najvar; Annette W. Fothergill; Rosie Bocanegra; Marcos Olivo; Dora I. McCarthy; William R. Kirkpatrick; Yoshiko Fukuda; Junichi Mitsuyama; Thomas F. Pattersona

doi:10.1128/AAC.04228-14

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

Nathan P. Wiederhold, Laura K. Najvar, Annette W. Fothergill, Rosie Bocanegra, Marcos Olivo, Dora I. McCarthy, William R. Kirkpatrick, Yoshiko Fukuda, Junichi Mitsuyama, Thomas F. Pattersona

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

Original language	English (US)
Pages (from-to)	1341-1343
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	59
Issue number	2
DOIs	https://doi.org/10.1128/AAC.04228-14
State	Published - Feb 1 2015

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.04228-14

Cite this

Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Kirkpatrick, W. R., Fukuda, Y., Mitsuyama, J., & Pattersona, T. F. (2015). The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans. Antimicrobial agents and chemotherapy, 59(2), 1341-1343. https://doi.org/10.1128/AAC.04228-14

Wiederhold, NP, Najvar, LK, Fothergill, AW, Bocanegra, R, Olivo, M, McCarthy, DI, Kirkpatrick, WR, Fukuda, Y, Mitsuyama, J & Pattersona, TF 2015, 'The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans', Antimicrobial agents and chemotherapy, vol. 59, no. 2, pp. 1341-1343. https://doi.org/10.1128/AAC.04228-14

@article{5c0c35bca48e44888b64c1d01605bd29,

title = "The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans",

abstract = "We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.",

author = "Wiederhold, {Nathan P.} and Najvar, {Laura K.} and Fothergill, {Annette W.} and Rosie Bocanegra and Marcos Olivo and McCarthy, {Dora I.} and Kirkpatrick, {William R.} and Yoshiko Fukuda and Junichi Mitsuyama and Pattersona, {Thomas F.}",

year = "2015",

month = feb,

day = "1",

doi = "10.1128/AAC.04228-14",

language = "English (US)",

volume = "59",

pages = "1341--1343",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

TY - JOUR

T1 - The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

AU - Wiederhold, Nathan P.

AU - Najvar, Laura K.

AU - Fothergill, Annette W.

AU - Bocanegra, Rosie

AU - Olivo, Marcos

AU - McCarthy, Dora I.

AU - Kirkpatrick, William R.

AU - Fukuda, Yoshiko

AU - Mitsuyama, Junichi

AU - Pattersona, Thomas F.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

AB - We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

UR - http://www.scopus.com/inward/record.url?scp=84921901154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921901154&partnerID=8YFLogxK

U2 - 10.1128/AAC.04228-14

DO - 10.1128/AAC.04228-14

M3 - Article

C2 - 25451054

AN - SCOPUS:84921901154

SN - 0066-4804

VL - 59

SP - 1341

EP - 1343

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

ER -

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this